SCHEMBL25291133

SCHEMBL25291133

CC(C)c1ccc(-c2nc3ncccn3c2CN2CCC3CCC(C2)N3C=O)cc1

nearest known ligand 0.65

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ KCNK3 O14649 20/20 0.65
▸ KCNK9 Q9NPC2 20/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30417973 0.95 KCNK3 (0.69) KCNK3KCNK9
SCHEMBL25238913 0.88 KCNK3 (0.69) KCNK3KCNK9
SCHEMBL30359090 0.87 KCNK3 (0.64) KCNK3KCNK9
SCHEMBL30501186 0.83 KCNK3 (0.68) KCNK3KCNK9
SCHEMBL22636283 0.83 KCNK3 (0.70) KCNK3KCNK9
SCHEMBL25280052 0.83 KCNK3 (0.71) KCNK3KCNK9
SCHEMBL21826492 0.81 KCNK3 (0.79) KCNK3KCNK9
SCHEMBL20588935 0.81 KCNK3 (0.68) KCNK3KCNK9
SCHEMBL30417275 0.80 KCNK3 (0.63) KCNK3KCNK9
SCHEMBL22001660 0.79 KCNK3 (1.00) KCNK3KCNK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4452264-A1 COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A NOREPINEPHRINE REUPTAKE INHIBITOR FOR THE TREATMENT OF SLEEP APNEA Bayer Aktiengesellschaft (DE) 2024-10-30 — — EP disclosed
EP-4452263-A1 COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A P2X3 RECEPTOR ANTAGONIST FOR THE TREATMENT OF SLEEP APNEA Bayer Aktiengesellschaft (DE) 2024-10-30 — — EP disclosed
WO-2023118126-A1 COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A NOREPINEPHRINE REUPTAKE INHIBITOR FOR THE TREATMENT OF SLEEP APNEA BAYER AKTIENGESELLSCHAFT (DE) 2023-06-29 — — WO disclosed
WO-2023118122-A1 COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A P2X3 RECEPTOR ANTAGONIST FOR THE TREATMENT OF SLEEP APNEA BAYER AKTIENGESELLSCHAFT (DE) 2023-06-29 — — WO disclosed
Send feedback